Drugs / AZD9750
last change Jan 2026 re-read 2 minutes ago

AZD9750

Developed for
prostate cancer
Investigated by
AstraZeneca

Trials 1 · a red edge is where a trial was stopped

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07336446 Jan 2026 → Jan 2029 expected prostate cancer AstraZeneca Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AZD9750 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07336446